198 related articles for article (PubMed ID: 34328656)
1. High level of phosphatidylcholines/lysophosphatidylcholine ratio in urine is associated with prostate cancer.
Li X; Nakayama K; Goto T; Kimura H; Akamatsu S; Hayashi Y; Fujita K; Kobayashi T; Shimizu K; Nonomura N; Ogawa O; Inoue T
Cancer Sci; 2021 Oct; 112(10):4292-4302. PubMed ID: 34328656
[TBL] [Abstract][Full Text] [Related]
2. Comparative evaluation of the extraction and analysis of urinary phospholipids and lysophospholipids using MALDI-TOF/MS.
Li X; Nakayama K; Goto T; Akamatsu S; Shimizu K; Ogawa O; Inoue T
Chem Phys Lipids; 2019 Sep; 223():104787. PubMed ID: 31255592
[TBL] [Abstract][Full Text] [Related]
3. Parameters affecting the accuracy of the MALDI-TOF MS determination of the phosphatidylcholine/lysophosphatidylcholine (PC/LPC) ratio as potential marker of spermatozoa quality.
Bresler K; Pyttel S; Paasch U; Schiller J
Chem Phys Lipids; 2011 Oct; 164(7):696-702. PubMed ID: 21827741
[TBL] [Abstract][Full Text] [Related]
4. Decreased expression of lysophosphatidylcholine (16:0/OH) in high resolution imaging mass spectrometry independently predicts biochemical recurrence after surgical treatment for prostate cancer.
Goto T; Terada N; Inoue T; Kobayashi T; Nakayama K; Okada Y; Yoshikawa T; Miyazaki Y; Uegaki M; Utsunomiya N; Makino Y; Sumiyoshi S; Yamasaki T; Kamba T; Ogawa O
Prostate; 2015 Dec; 75(16):1821-30. PubMed ID: 26332786
[TBL] [Abstract][Full Text] [Related]
5. The C-terminal fragment of prostate-specific antigen, a 2331 Da peptide, as a new urinary pathognomonic biomarker candidate for diagnosing prostate cancer.
Nakayama K; Inoue T; Sekiya S; Terada N; Miyazaki Y; Goto T; Kajihara S; Kawabata S; Iwamoto S; Ikawa K; Oosaga J; Tsuji H; Tanaka K; Ogawa O
PLoS One; 2014; 9(9):e107234. PubMed ID: 25233230
[TBL] [Abstract][Full Text] [Related]
6. Urinary prostate specific antigen: is the clinical use likely?
Pejcic T; Hadzi-Djokic J; Acimovic M; Topuzovic C; Milkovic B; Janjic A
Acta Chir Iugosl; 2005; 52(4):69-74. PubMed ID: 16673599
[TBL] [Abstract][Full Text] [Related]
7. New approach in determination of urinary diagnostic markers for prostate cancer by MALDI-TOF/MS.
Buszewska-Forajta M; Pomastowski P; Monedeiro F; Król-Górniak A; Adamczyk P; Markuszewski MJ; Buszewski B
Talanta; 2022 Jan; 236():122843. PubMed ID: 34635233
[TBL] [Abstract][Full Text] [Related]
8. Proteomic analysis of voided urine after prostatic massage from patients with prostate cancer: a pilot study.
Rehman I; Azzouzi AR; Catto JW; Allen S; Cross SS; Feeley K; Meuth M; Hamdy FC
Urology; 2004 Dec; 64(6):1238-43. PubMed ID: 15596215
[TBL] [Abstract][Full Text] [Related]
9. Serum-to-urinary prostate-specific antigen ratio in patients with benign prostatic hyperplasia and prostate cancer.
Hillenbrand M; Bastian M; Steiner M; Zingler C; Müller M; Wolff JM; Seiter H; Schuff-Werner P
Anticancer Res; 2000; 20(6D):4995-6. PubMed ID: 11326656
[TBL] [Abstract][Full Text] [Related]
10. A novel urinary mRNA signature using the droplet digital polymerase chain reaction platform improves discrimination between prostate cancer and benign prostatic hyperplasia within the prostate-specific antigen gray zone.
Kang HW; Lee HY; Byun YJ; Jeong P; Yoon JS; Kim DH; Kim WT; Kim YJ; Lee SC; Yun SJ; Kim WJ
Investig Clin Urol; 2020 Jul; 61(4):411-418. PubMed ID: 32665998
[TBL] [Abstract][Full Text] [Related]
11. Visualization of phosphatidylcholine, lysophosphatidylcholine and sphingomyelin in mouse tongue body by matrix-assisted laser desorption/ionization imaging mass spectrometry.
Enomoto H; Sugiura Y; Setou M; Zaima N
Anal Bioanal Chem; 2011 Jun; 400(7):1913-21. PubMed ID: 21472363
[TBL] [Abstract][Full Text] [Related]
12. Urinary CD14 as a potential biomarker for benign prostatic hyperplasia - discovery by combining MALDI-TOF-based biostatistics and ESI-MS/MS-based stable-isotope labeling.
Cheng HL; Huang HJ; Ou BY; Chow NH; Chen YW; Tzai TS; Wu CJ; Chen SH
Proteomics Clin Appl; 2011 Apr; 5(3-4):121-32. PubMed ID: 21322116
[TBL] [Abstract][Full Text] [Related]
13. Comparison of mRNA, Protein, and Urinary Nucleic Acid Levels of S100A8 and S100A9 between Prostate Cancer and BPH.
Yun SJ; Yan C; Jeong P; Kang HW; Kim YH; Kim EA; Lee OJ; Kim WT; Moon SK; Kim IY; Choi YH; Kim WJ
Ann Surg Oncol; 2015 Jul; 22(7):2439-45. PubMed ID: 25348783
[TBL] [Abstract][Full Text] [Related]
14. Detection of pre-neoplastic and neoplastic prostate disease by MALDI profiling of urine.
M'Koma AE; Blum DL; Norris JL; Koyama T; Billheimer D; Motley S; Ghiassi M; Ferdowsi N; Bhowmick I; Chang SS; Fowke JH; Caprioli RM; Bhowmick NA
Biochem Biophys Res Commun; 2007 Feb; 353(3):829-34. PubMed ID: 17194448
[TBL] [Abstract][Full Text] [Related]
15. Detection of individual phospholipids in lipid mixtures by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry: phosphatidylcholine prevents the detection of further species.
Petkovic M; Schiller J; Müller M; Benard S; Reichl S; Arnold K; Arnhold J
Anal Biochem; 2001 Feb; 289(2):202-16. PubMed ID: 11161314
[TBL] [Abstract][Full Text] [Related]
16. Urinary Polyamines: A Pilot Study on Their Roles as Prostate Cancer Detection Biomarkers.
Tsoi TH; Chan CF; Chan WL; Chiu KF; Wong WT; Ng CF; Wong KL
PLoS One; 2016; 11(9):e0162217. PubMed ID: 27598335
[TBL] [Abstract][Full Text] [Related]
17. Application of matrix-assisted laser desorption/ionization time-of-flight mass spectrometry for monitoring the digestion of phosphatidylcholine by pancreatic phospholipase A(2).
Petković M; Müller J; Müller M; Schiller J; Arnold K; Arnhold J
Anal Biochem; 2002 Sep; 308(1):61-70. PubMed ID: 12234464
[TBL] [Abstract][Full Text] [Related]
18. MALDI MS profiling of post-DRE urine samples highlights the potential of β-microseminoprotein as a marker for prostatic diseases.
Flatley B; Wilmott KG; Malone P; Cramer R
Prostate; 2014 Jan; 74(1):103-11. PubMed ID: 24115268
[TBL] [Abstract][Full Text] [Related]
19. Serum proteomic profiling can discriminate prostate cancer from benign prostates in men with total prostate specific antigen levels between 2.5 and 15.0 ng/ml.
Ornstein DK; Rayford W; Fusaro VA; Conrads TP; Ross SJ; Hitt BA; Wiggins WW; Veenstra TD; Liotta LA; Petricoin EF
J Urol; 2004 Oct; 172(4 Pt 1):1302-5. PubMed ID: 15371828
[TBL] [Abstract][Full Text] [Related]
20. Simultaneous Analysis of Multiple Cancer Biomarkers Using MALDI-TOF Mass Spectrometry Based on a Parylene-Matrix Chip.
Park JM; Kim MJ; Noh JY; Yun TG; Kang MJ; Lee SG; Yoo BC; Pyun JC
J Am Soc Mass Spectrom; 2020 Apr; 31(4):917-926. PubMed ID: 32154716
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
